)
)
)
ImmuneOnco is a Hong Kong-listed (Stock Code: HK.1541) clinical-stage biotechnology company dedicated to discovering and developing immunotherapies for the treatment of cancer and other diseases. Timdarpacept, a SIRPα-IgG1 Fc fusion protein, is currently in Phase III clinical development for the first-line treatment of chronic myelomonocytic leukemia (CMML), with a potential Biologics License Application (BLA) submission by the end of 2026. Amulirafuspalfa, a first-in-class CD47×CD20 bispecific antibody, is on the verge of initiating Phase III study. It is being evaluated for the treatment of relapsed/refractory (R/R) follicular lymphoma (end of Phase II) and systemic lupus erythematosus (SLE, Phase Ib). IMC-003 (an ActR2A-Fc fusion protein) — featuring enhanced affinity and potent blocking activity — is in Phase I for the treatment of pulmonary arterial hypertension (PAH). A trispecific candidate targeting GDF-9/ActR2A/ActR2B is currently in the preclinical stage.
Year Founded
2015
Next catalyst (value inflection) update
Amulirafuspalfa Phase III start in 2026 and timdarpacept Phase III readout by the end of 2026
Expected time of next catalyst update
Amulirafuspalfa Phase III start in H1 2026 and timdarpacept Phase III readout by the end of 2026
City
Shanghai
Country
China
Company CEO or top company official
Wenzhi Tian
Development Phase of Primary Product
Phase III
Exchange
Hong Kong Stock Exchange
Lead Product in Development
Timdarpacept, a SIRPα-IgG1 Fc fusion protein, is currently in Phase III clinical development for the first-line treatment of chronic myelomonocytic leukemia (CMML), with a potential Biologics License Application (BLA) submission by the end of 2026. Amulirafuspalfa, a first-in-class CD47×CD20 bispecific antibody, is on the verge of initiating Phase III study. It is being evaluated for the treatment of relapsed/refractory (R/R) follicular lymphoma (end of Phase II) and systemic lupus erythematosus (SLE, Phase Ib).
Number of Unlicensed Products
Timdarpacept, a SIRPα-IgG1 Fc fusion protein, is currently in Phase III clinical development for the first-line treatment of chronic myelomonocytic leukemia (CMML), with a potential Biologics License Application (BLA) submission by the end of 2026. Amuli
Therapeutic Area
Oncology
Ticker
1541.HK
Website
https://cn.immuneonco.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
